4//SEC Filing
Krause Kevin Michael 4
Accession 0001610717-24-000027
CIK 0001880438other
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 7:59 PM ET
Size
12.4 KB
Accession
0001610717-24-000027
Insider Transaction Report
Form 4
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-09$6.60/sh+5,000$33,000→ 9,331 total - Sale
Common Stock
2024-01-09$20.14/sh−7,417$149,367→ 1,914 total - Exercise/Conversion
Common Stock
2024-01-09$0.42/sh+2,417$1,015→ 4,331 total - Exercise/Conversion
Stock Option (right to buy)
2024-01-09−2,417→ 49,868 totalExercise: $0.42Exp: 2030-01-22→ Common Stock (2,417 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-01-09−5,000→ 26,832 totalExercise: $6.60Exp: 2031-04-29→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
- [F4]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001916925
Filing Metadata
- Form type
- 4
- Filed
- Jan 10, 7:00 PM ET
- Accepted
- Jan 11, 7:59 PM ET
- Size
- 12.4 KB